The EMA human medicines committee (CHMP) has recently issued a statement on Obeticholic acid for the treatment of Primary Biliary Cholangitis (PBC). The CHMP recommended to the European Commission that the market authorisation for Obeticholic acid in the European Union (EU) be revoked (https://ww…
• First patient enrolled at Hôpital Beaujon, Clichy, France • The COMBAT Trial is a multicenter, randomized, open-label, Phase II clinical trial in patients with decompensated cirrhosis Barcelona, Spain, 9th July 2024 – DECISION, an EU-funded research consortium in liver disease research, is plea…
The European Association for the Study of the Liver (EASL)is delighted to announce that JHEP Reports, its Open Access publication, achieved an impressive impact factor of 9.5 in the 2024 release of Journal Citation Reports (JCR) by Clarivate. This notable accomplishment underscores the journal’s …
The European Association for the Study of the Liver (EASL) is proud to announce that the Journal of Hepatology, its flagship publication, achieved an impact factor of 26.8 in the 2024 release of Journal Citation Reports (JCR) by Clarivate, solidifying its position as the premier journal in the fi…
The European Association for the Study of the Liver (EASL) is proud to announce the appointment of Prof. Vlad Ratziu as the new Editor-in-Chief of the Journal of Hepatology, the premier publication in the field of liver research. This prestigious appointment was confirmed by the EASL Governing Bo…
Introducing the EASL Guidelines App – your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Developed by EASL, the European Association for the Study of the Liver, this app is meticulously designed to support healthcare professi…
The GENIAL project is dedicated to enhancing our understanding of the early stages of alcohol-related hepatocellular carcinoma (ALD-HCC) by integrating clinical hepatology expertise with artificial intelligence (AI). This innovative initiative, as explained by project coordinator Eric Trépo, aims…
THRIVE is an EU-founded initiative that brings together a strong and multidisciplinary team with 13 partners, from 8 countries, with complementary expertise in liver cancer research and in the use of cutting-edge technologies. The overall aim of the THRIVE project is to improve the outcome of bot…
GENIAL is a pioneering initiative targeting alcohol-related liver cancer (ALD-HCC). Our primary goal is to identify genetic and environmental factors contributing to ALD-HCC risk and unravel how their interactions drive alcohol-related liver carcinogenesis. By pinpointing individuals at risk, GEN…
The LIVERAIM project’s overall goal is to set up a screening platform to detect cases of liver disease early on, so that patients can take steps to protect their liver before it’s too late. As the silent phase of the disease can last for two decades, there is a clear window of opportunity to take…
